Niall Martin, Artios CEO
December 3, 2020 07:14 AM ESTUpdated 08:02 AM
Deals

Mer­ck KGaA bets big on DNA dam­age up­start, push­ing $30M up­front and hefty in­cen­tives for a Lyn­parza pi­o­neer

Jason Mast

Editor

The DNA dam­age spe­cial­ists over at Ar­tios Phar­ma have re­mained large­ly qui­et in the 2 1/2 years since their last fundraise, but what­ev­er they’ve been …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times